https://www.selleckchem.com/pr....oducts/clozapine-n-o
Treatment of SARS-CoV-2 with bamlanivimab in immunocompromised patients results in the rapid development of immune escape variants in a significant proportion of cases. Given that the E484K mutation can hamper natural immunity, the effectiveness of vaccination as well as antibody-based therapies, these findings may have important implications not only for individual treatment decisions but may also pose a risk to general prevention and treatment strategies. All authors are employed and all expenses covered by governmental, fed
Like
Comment
Share
